Collegium raises 2025 guidance as Q3 net revenue rises 31% to $209.4 million
Collegium Pharmaceutical reported third-quarter 2025 results on November 6, 2025, with product revenues, net of $209.4 million, up 31% from a year earlier, and GAAP diluted earnings of $0.84 per share versus $0.27. The company raised its full-year 2025 product revenue guidance to $775 million to $785 million and its adjusted EBITDA guidance to $460 million to $470 million, which supports the outlook for shareholders.
Key points
- Q3 2025 product revenues, net were $209.4 million versus $159.3 million in Q3 2024; Jornay PM net revenue was $41.8 million.
- GAAP net income was $31.5 million, or $0.84 diluted EPS, versus $9.3 million, or $0.27, a year earlier; adjusted EPS was $2.25 versus $1.61.
- Full-year 2025 product revenue guidance was raised to $775 million to $785 million from $745 million to $760 million; adjusted EBITDA guidance was raised to $460 million to $470 million from $440 million to $455 million.
- Board authorized a share repurchase program of up to $150 million through December 31, 2026; cash, cash equivalents and marketable securities were $285.9 million at quarter end.
The filing
Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.